Long COVID research has produced dozens of findings across virology, immunology, neuroscience, and metabolism. Viral persistence. Epigenetic reprogramming. Chronic fatigue signals. Self-sustaining inflammation. They read like separate stories—until you look at which cell keeps showing up in all of them.
The monocyte. An ordinary white blood cell. Not flashy like T cells, not famous like antibodies. But across six independent lines of Long COVID research, the monocyte sits at the center—not as bystander, but as active participant. It harbors virus. It drives fatigue. It locks itself into a state of chronic inflammation. And it creates the conditions that make single-target treatments fail.
Here is the case for the monocyte as the cell that holds Long COVID together.
Thread 1: The Reservoir
In 2021, Bruce Patterson’s team reported something unexpected: SARS-CoV-2 spike protein S1 subunit could be detected inside CD16+ non-classical monocytes of patients with post-acute sequelae up to 15 months after infection. They confirmed the protein by mass spectrometry—this was not artifact. Across studies, approximately 64% of PASC patients had detectable circulating S1, with higher levels in those with ongoing symptoms.
In 2023, researchers at Institut Pasteur and CEA showed something even more striking: replication-competent SARS-CoV-2 persists in alveolar macrophages for more than six months in a macaque model. The virus wasn’t just leaving protein fragments behind—it was actively replicating inside the cells meant to destroy it.
The monocyte is not just carrying viral debris. It may be a viral sanctuary.
Thread 2: The Fatigue Signal
In February 2026, a Cambridge University team published a study in Science Advances that identified the molecular signature of Long COVID fatigue. They found that peripheral blood mononuclear cells from Long COVID patients spontaneously release interferon-gamma (IFN-γ) without any external stimulation—something healthy immune cells never do.
The source: CD8+ T cells responding to viral antigens presented by CD14+ monocytes. The monocytes were showing fragments of SARS-CoV-2 to T cells, and the T cells were responding with IFN-γ. Continuously. For months.
The clinical correlate was striking. IFN-γ therapy—given to cancer patients—causes fatigue, myalgia, and depression. Exactly the symptoms of Long COVID. Over a 2.5-year follow-up, more than 60% of patients saw symptom resolution, and in every case, their IFN-γ levels dropped in parallel. The fatigue wasn’t mysterious. It was IFN-γ, driven by monocytes presenting persistent antigen.
Thread 3: The Paradox
Here is where it gets cruel.
IFN-γ is supposed to be the immune system’s antiviral weapon. And in many contexts, it is—Huot et al. showed that IFN-γ does inhibit SARS-CoV-2 replication in macrophages. So the T cells are doing exactly what they should.
But IFN-γ simultaneously upregulates MHC-E on the surface of those same macrophages. MHC-E is a “don’t kill me” signal to NK cells. Normally, when a cell is infected, NK cells recognize it and destroy it. But MHC-E blocks that recognition.
So the immune system faces a triple bind:
- IFN-γ fights the virus inside macrophages
- IFN-γ shields infected macrophages from NK cell killing
- IFN-γ causes the symptoms of fatigue, pain, and cognitive dysfunction
The molecule that fights the infection also protects the infected cells and makes the patient sick. This is the IFN-γ paradox, and it may explain why no single-target drug has worked: suppressing IFN-γ might ease symptoms but allow viral persistence to worsen. Boosting it might help clear virus but intensify symptoms and further shield infected cells from NK killing.
Notably, the Pasteur group observed that macaques who cleared virus more effectively had “adaptive NK cells” that could bypass MHC-E inhibition. Whether some Long COVID patients lack these adaptive NK cells remains an open question.
Thread 4: The Epigenetic Lock
Monocytes are short-lived cells—they survive days to weeks in circulation. So how does the dysfunction persist for months or years?
The answer lies upstream, in the bone marrow. During acute COVID-19, the cytokine storm—particularly IL-6—reprograms hematopoietic stem and progenitor cells (HSPCs). These are the cells that produce new monocytes. The reprogramming is epigenetic: changes in histone acetylation (particularly H3K27ac) and chromatin accessibility that don’t alter DNA sequence but permanently change gene expression.
The result: every new monocyte born from these reprogrammed HSPCs arrives already “trained” into a hyper-inflammatory state. ATAC-seq studies show these chromatin changes persist more than 12 months after acute infection. When stimulated, post-COVID monocytes produce up to 100-fold more pro-inflammatory cytokines than those from healthy controls.
This is trained immunity gone wrong. The bone marrow remembers the infection and keeps producing angry monocytes long after the original trigger is gone. IL-6 receptor blockade (tocilizumab) has been shown to partially reverse this reprogramming in mouse models—reducing both the frequency and inflammatory potential of new monocytes.
Thread 5: The LC-Mo State
In January 2026, a study in Nature Immunology identified a distinct monocyte transcriptional state unique to Long COVID patients—they called it LC-Mo.
LC-Mo cells are not simply “activated” monocytes. They express a specific gene signature including TREM2 and APOE—markers associated with tissue remodeling and fibrosis. They show persistent elevation of CCL2, CXCL11, and TNF. And when researchers looked at bronchoalveolar lavage fluid, they found LC-Mo-like macrophages with a profibrotic profile in the lungs.
Critically, the LC-Mo state correlated with fatigue severity and respiratory symptoms. These weren’t just abnormal lab values—they tracked with what patients actually felt.
Perhaps most concerning: LC-Mo cells showed impaired interferon responses when stimulated. The very cells that should mount antiviral defense were blunted—even as they drove chronic inflammation through other pathways. They were simultaneously too inflammatory and not antiviral enough.
Thread 6: The Self-Sustaining Loop
Even if every virus particle were cleared tomorrow, the monocyte might still sustain its own inflammation.
Activated monocytes and neutrophils release S100A8/A9, also known as calprotectin—a damage-associated molecular pattern (DAMP) that constitutes roughly 40% of the cytosolic protein in these cells. Extracellular S100A8/A9 binds TLR4 and RAGE receptors on neighboring immune cells, activating NF-κB and the NLRP3 inflammasome. This triggers production of IL-1β, IL-6, and TNF-α—which in turn stimulate more S100A8/A9 release.
The result is a self-sustaining pro-inflammatory feedback loop that can operate independently of any viral trigger. Research has confirmed that S100A8/A9 remains elevated in post-ICU COVID patients months after infection and correlates negatively with lung function. Half of Long COVID patients show elevated IL-1β, IL-6, TNF-α, and S100A8/A9 without any detectable viral protein or RNA.
In acute COVID mouse models, paquinimod—a small-molecule S100A8/A9 inhibitor—blocks TLR4-mediated signaling, reduces viral loads, and eliminates aberrant neutrophils. No one has yet tested it in Long COVID. That gap should be closed.
A Natural Resolution?
Amid these interlocking traps, there is one intriguing signal of hope. A 2022 study in Frontiers in Immunology found that 22.6% of COVID-19 convalescents develop anti-calprotectin autoantibodies—and these individuals were significantly more likely to report full clinical recovery eight months after infection.
The body, in some patients, appears to mount its own attack on the S100A8/A9 feedback loop. It develops antibodies against the very molecule sustaining chronic inflammation. Whether these autoantibodies are causally protective or merely markers of a healthier immune response is unknown. But the correlation is striking: block the DAMP signal, break the loop, recover.
Why Single-Target Treatments Fail
The Monocyte Trap explains a pattern that has frustrated the Long COVID field: treatment after treatment failing in clinical trials. Paxlovid (antivirals alone), BC007 (autoantibody neutralization), temelimab (anti-retroviral envelope), RECOVER-NEURO (brain stimulation)—none demonstrated clear benefit.
The monocyte is doing too many things simultaneously. Block viral persistence without addressing epigenetic lock-in, and trained monocytes continue the inflammation. Suppress IFN-γ without clearing virus, and the reservoir persists. Target one cytokine while the DAMP loop sustains the others.
The IFN-γ paradox alone creates a therapeutic double bind. But layered on top of epigenetic persistence, a profibrotic transcriptional state, and a self-amplifying DAMP loop, the challenge becomes clear: Long COVID treatment likely requires combination approaches that address multiple points of the monocyte’s dysfunction simultaneously.
Therapeutic Implications
If the monocyte is the central node, then several current and potential interventions make mechanistic sense:
- JAK inhibitors (baricitinib): Block downstream IFN-γ signaling via JAK1/2. The REVERSE-LC trial has expanded to 17 sites with 550 patients. This addresses Thread 2 (fatigue signal) and partially Thread 3 (the paradox). Results expected late 2026.
- IL-6 receptor antagonists (tocilizumab): Break the epigenetic reprogramming cycle at the HSPC level. An emulated target trial in RA patients showed 58% lower diagnosed Long COVID. This addresses Thread 4 (the epigenetic lock). Formal trials needed.
- S100A8/A9 inhibitors (paquinimod): Block the self-sustaining DAMP feedback loop. Proven in acute COVID mouse models. Never tested in Long COVID. This addresses Thread 6. A critical gap.
- Combination approach: An antiviral (to reduce reservoir) + JAK inhibitor (to dampen IFN-γ) + IL-6R blockade (to break epigenetic lock) could theoretically attack multiple arms simultaneously. No such trial exists yet.
What Comes Next
The monocyte did not cause Long COVID. The virus did. But the monocyte may be the reason it persists—a cell trapped between fighting an infection it cannot clear, sustaining inflammation it cannot stop, and replicating a dysfunctional program it was trained to follow.
Understanding this cell—its paradoxes, its epigenetic scars, its self-reinforcing loops—may be the key to finally designing treatments that work. Not by targeting one pathway, but by freeing the monocyte from the trap it’s caught in.
Key Sources
- Patterson et al. — Frontiers in Immunology (2021): S1 protein persistence in CD16+ monocytes up to 15 months
- Huot et al. — Nature Immunology (Nov 2023): Replication-competent SARS-CoV-2 in alveolar macrophages, IFN-γ paradox
- Krishna et al. — Science Advances (Feb 2026): Spontaneous IFN-γ release as Long COVID fatigue biomarker
- Li et al. — Nature Immunology (Jan 2026): LC-Mo monocyte transcriptional state
- Li et al. — Science Translational Medicine (2024): IFN-γ drives respiratory PASC via monocyte-derived macrophages
- McMillan, Turner, Uhal — Int J Mol Sci (Dec 2025): Central role of macrophages in LC pathophysiology
- Moody et al. — Frontiers in Immunology (2022): Anti-calprotectin autoantibodies and recovery
- Holms — Immuno/MDPI (2022): TLR4/RAGE self-sustaining S100A8/A9 loop model
- Kildal et al. — BMC Infectious Diseases (March 2026): Serial calprotectin and DNase measurements over 1 year
- Butzin-Dozier et al. — medRxiv (2026): IL-6R antagonists and Long COVID risk reduction